<DOC>
	<DOCNO>NCT02218164</DOCNO>
	<brief_summary>The purpose study find combination two establish anti-cancer therapy beneficial patient squamous cell carcinoma skin . Specifically , investigator want determine combination 5-FU/Capecitabine ( oral pill ) Interferon alpha-2b ( injection ) help people advanced case squamous cell carcinoma skin . For participant approve oral capecitabine , treat physician use continuous infusion 5-FU . Both 5-FU/Capecitabine Interferon alpha-2b use separately treat squamous cell carcinoma skin FDA approve cancer type .</brief_summary>
	<brief_title>Capecitabine 5-FU With Pegylated Interferon Alpha-2b Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must histologically cytologically confirm squamous cell carcinoma skin . Potential participant present `` squamous cell carcinoma unknown primary lesion '' time diagnosis eligible patient plausible primary skin site remove past . Similarly , potential participant neck , parotid , facial lymph node positive squamous cell carcinoma identifiable mucosal primary would also eligible . Must measurable disease , define Response accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 least one lesion accurately measure least one dimension &gt; 10 mm CT , MRI , caliper There limitation prior treatment local , regional , topical systemic agent , except prior systemic treatment 5fluorouracil prodrugs thereof . Prior topical treatment 5fluorouracil permit . Patients chronic daily dos prednisone great 10 mg exclude . There restriction timing last treatment long patient recover expected toxicity least 21 day pass since last administration . Life expectancy great 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 ( Karnofsky &gt; =60 % Must normal organ marrow function Must candidate curative locoregional treatment . Patients recurrent locoregional disease follow surgery and/or radiation resection unacceptably morbid unlikely curative eligible . Women childbearing potential men must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document Have chemotherapy radiotherapy within 21 day ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 3 week earlier May receive investigational agent Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition either 5FU/Capecitabine Interferon Uncontrolled , ongoing illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Women pregnant breastfeed Any heart lung transplant patient immunosuppressive agent . Renal transplant patient allow patient willing reduce immunosuppressive agent understand risk rejection possible need return dialysis . Patients CLL hematologic malignancy allow long meet criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>cutaneous</keyword>
	<keyword>skin cancer</keyword>
</DOC>